Trial	Safety			Immunogenicity
	Serious AE	Reactogenicity	AE to discontinuation	Vaccine virus shedding	Seroconversion
RV1 Anh 2011‐PHL	X	X	X	‐	X
RV1 Anh 2011‐VNM	X	X	X	‐	X
RV1 Bernstein 1998‐USA	X	X	X	X	X
RV1 Bernstein 1999‐USA	‐	X	‐	X	X
RV1 Colgate 2016‐BGD	‐	‐	‐	‐	‐
RV1 Dennehy 2005‐NA	X	X	X	X	X
RV1 GSK[021] 2007‐PAN	X	X	X	X	X
RV1 GSK[033] 2007‐LA	X	X	X	X	X
RV1 GSK[041] 2007‐KOR	X	X	X	‐	X
RV1 GSK[101555] 2008‐PHL	X	X	X	X	X
RV1 Kawamura 2011‐JPN	X	X	X	‐	X
RV1 Kerdpanich 2010‐THA	X	X	X	X	X
RV1 Kim 2012‐KOR	X	X	X	‐	X
RV1 Li 2013a‐CHN	X	X	X	X	X
RV1 Li 2013b‐CHN	‐	‐	‐	‐	‐
RV1 Li 2014‐CHN	X	X	X	‐	X
RV1 Madhi 2010‐AF	X	‐	‐	‐	‐
RV1 Narang 2009‐IND	X	X	X	‐	X
RV1 NCT00158756‐RUS	X	‐	X	‐	X
RV1 Omenaca 2012‐EU	X	X	‐	‐	X
RV1 Phua 2005‐SGP	X	X	Xa	Xa	X
RV1 Phua 2009‐AS	X	‐	X	‐	‐
RV1 Rivera 2011‐DOM	X	X	‐	‐	X
RV1 Ruiz‐Palac 06‐LA/EU	X	X	X	‐	Xa
RV1 Salinas 2005‐LA	X	X	‐	X	X
RV1 Steele 2008‐ZAF	X	X	X	X	X
RV1 Steele 2010a‐ZAF	X	Xa	‐	X	X
RV1 Steele 2010b‐ZAF	X	X	X	X	X
RV1 Tregnaghi 2011‐LA	X	‐	X	‐	X
RV1 Vesikari 2004a‐FIN	X	X	X	X	X
RV1 Vesikari 2004b‐FIN	X	X	X	‐	X
RV1 Vesikari 2007a‐EU	X	X	‐	‐	X
RV1 Vesikari 2011‐FIN	X	X	X	X	X
RV1 Ward 2006‐USA		Xa	‐	X	Xa
RV1 Zaman 2009‐BGD	X	X	‐	X	X
RV1 Zaman 2017‐BGD	X	‐	‐	‐	‐
RV5 Armah 2010‐AF	X	Xa	X	‐	X
RV5 Block 2007‐EU/USA	X	X	X	‐	X
RV5 Ciarlet 2009‐EU	X	X	‐	‐	X
RV5 Clark 2003‐USA	X	X	X	X	X
RV5 Clark 2004‐USA	Xa	X	X	X	X
RV5 Dhingra 2014‐IND	X	X	X	X	X
RV5 Iwata 2013‐JPN	Xa	X	X	‐	‐
RV5 Kim 2008‐KOR	X	Xa	‐	‐	Xa
RV5 Lawrence 2012‐CHN	X	Xa	X	X	‐
RV5 Levin 2017‐AF	X	X	X	X	X
RV5 Merck[009] 2005‐USA	X	X	X	‐	‐
RV5 Mo 2017‐CHN	X	X	X	‐	‐
RV5 Vesikari 2006a‐FIN	X	X	X	‐	X
RV5 Vesikari 2006b‐INT	X	X	Xa	‐	X
RV5 Zaman 2010‐AS	X	Xa	X	‐	Xa
VAC Bhandari 2006‐IND	X	X	‐	X	‐
VAC Bhandari 2009‐IND	X	X	‐	X	X
VAC Bhandari 2014‐IND	X	‐	‐	‐	X
VAC Chandola 2017‐IND	X	‐	‐	‐	X